Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE LAMIVUDINE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE LAMIVUDINE NEVIRAPINE.
EMTRICITABINE vs STAVUDINE; LAMIVUDINE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Stavudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase. Lamivudine is an NRTI that inhibits HIV reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV reverse transcriptase, causing enzyme inhibition.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (stavudine 30 mg + lamivudine 150 mg + nevirapine 200 mg) orally twice daily. For patients weighing ≥60 kg, stavudine 40 mg may be used; however, due to toxicity, 30 mg is preferred. Nevirapine requires a 14-day lead-in dose of 200 mg once daily.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Stavudine: 1.0-1.6 hours (mean ~1.5 h) in adults with normal renal function; prolonged in renal impairment. Lamivudine: 5-7 hours in adults; prolonged in renal impairment. Nevirapine: 25-30 hours (single dose); 40-45 hours with multiple dosing due to autoinduction.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Stavudine: Renal (approximately 60% unchanged) and hepatic metabolism. Lamivudine: Renal (approximately 70% unchanged) via glomerular filtration and active tubular secretion. Nevirapine: Hepatic metabolism (CYP3A4, CYP2B6) followed by renal excretion of metabolites (about 80% in urine, 10% in feces).
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."